Predictive value and clinical utility of centrally-assessed ER PgR and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive HER2-negative early breast cancer: TEXT and SOFT trials

摘要

PurposeThe SOFT and TEXT randomized phase III trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) early breast cancer. We investigated the prognostic and predictive value of centrally-assessed levels of estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 expression in women with HER2-negative disease.